This study tested a new treatment called mezigdomide, combined with dexamethasone, for people with multiple myeloma (a type of cancer). The treatment showed promise in patients who had already tried other treatments, including those resistant to lenalidomide and pomalidomide.
In the first phase of the study, they tested the treatment on 77 patients to determine the right dose and schedule and to check for side effects. The most common side effects were problems with the blood (neutropenia) and infections. Based on these results, they decided on the best dose and schedule for the next phase.
In the second phase, 101 patients received the treatment identified in the first phase. These patients had very advanced myeloma and had often tried other treatments, including anti-BCMA therapy. The most common side effects were blood problems and infections, but they were mostly reversible. The treatment led to an overall response in 41% of patients, with a median duration of response of 7.6 months.
In conclusion, the combination of mezigdomide and dexamethasone showed promise in patients with advanced multiple myeloma, with mainly manageable side effects.